Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that patients won't see these numbers and just throw up their hands in fear or resignation.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

Because of the large impact of prostate cancer, there is great interest in new methods of prevention and treatment; some of these appear to reduce mortality. [4] Lycopene is a natural product that ...

Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.